

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



27th May, 2022

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001

Company Code No. 524604

Dear Sir,

Sub: Outcome of Board Meeting and Submission of Audited Financial Results for the year ended on 31st March, 2022

We refer to our letter dated 5th May, 2022 informing the date of Meeting of the Board of Directors of the Company.

Please note that the Board of Directors in their meeting held today i.e. on 27th May, 2022, have approved the Audited Financial Results for the financial year 2021-22 ended on 31st March, 2022.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith:

1. Statement of Audited Financial Results for the year ended on 31st March, 2022.
2. Auditors' Report on the Audited Financial Results
3. Declaration to the effect that there is Unmodified Opinion with respect to Audited Financial Results for the year ended on 31st March, 2022

Thanking you,

Yours faithfully,

For ADLINE CHEM LAB LIMITED
(Formerly known as Kamron Laboratories Limited)

KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN: 00461198)

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

Kamlesh J. Laskari
MANAGING DIRECTOR

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



(Rs. In lakh)

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED ON 31ST MARCH, 2022

Particulars (Refer Notes Below)		Quarter ended on			Year ended on	
		31-03-2022 (Audited) (Refer notes)	31-12-2021 (Unaudited)	31-03-2021 (Audited) (Refer notes)	31-03-2022 (Audited)	31-03-2021 (Audited)
1	Revenue from operations	2.03	8.40	207.21	73.66	632.82
2	Other income	2.19	4.89	0.21	23.02	0.33
3	Total Income (1+2)	4.22	13.29	207.42	96.68	633.15
4	Expenses					
	a. Cost of Materials consumed	-	-	-	-	-
	b. Purchases of stock-in-trade	0.17	2.66	52.02	34.67	233.26
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.04	51.42	13.32	69.96
	d. Employee benefits expense	2.44	1.12	56.88	18.46	171.43
	e. Finance costs	0.30	-	2.37	0.74	3.27
	f. Depreciation & amortisation expense	(41.75)	25.59	16.29	35.01	102.34
	g. Other expenses	9.08	4.85	56.45	36.83	181.22
	Total Expenses	(29.76)	34.26	235.43	139.03	761.48
5	Profit/ (Loss) before exceptional items and tax (3-4)	33.98	(20.97)	(28.01)	(42.35)	(128.33)
6	Exceptional items	-	-	-	-	-
	Depreciation Written Back	114.14	-	-	114.14	-
7	Profit / (Loss) before tax (5-6)	148.12	(20.97)	(28.01)	71.79	(128.33)
8	Tax expense:					
	Current tax	-	-	-	-	-
	Deferred tax	-	-	-	-	-
9	Profit/ (Loss) for the period from continuing operations (7-8)	148.12	(20.97)	(28.01)	71.79	(128.33)
10	Profit/ (loss) from discontinuing operations before Tax	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/ (loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit/ (Loss) for the period (9+12)	148.12	(20.97)	(28.01)	71.79	(128.33)

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories.Ltd.)

Kamruni Contractor
MANAGING DIRECTOR

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Particulars	Quarter ended on			Year ended on	
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
	(Audited) (Refer notes)	(Unaudited)	(Audited) (Refer notes)	(Audited)	(Audited)
14 Other Comprehensive Income					
Items that will not be reclassified subsequently to profit or loss	-	-	-	-	-
Mention Item.....	-	-	-	-	-
Mention Item.....	-	-	-	-	-
Mention Item.....	-	-	-	-	-
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
Items that will be reclassified subsequently to profit or loss	-	-	-	-	-
Mention Item.....	-	-	-	-	-
Mention Item.....	-	-	-	-	-
Mention Item.....	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Other Comprehensive Income, net of tax	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14)	148.12	(20.97)	(28.01)	71.79	(128.33)
16 Paid-up equity shares capital (Face Value per share Rs. 10/-)	585.00	585.00	585.00	585.00	585.00
17 Reserves excluding Revaluation Reserves					
18 Earnings Per Share of Rs. 10/- each (for continuing operations)					
- Basic	2.53	(0.35)	(0.48)	1.23	(2.19)
- Diluted	2.53	(0.35)	(0.48)	1.23	(2.19)
19 Earnings Per Share of Rs. 10/- each (for discontinued operations)					
- Basic	-	-	-	-	-
- Diluted	-	-	-	-	-
20 Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)					
- Basic	2.53	(0.35)	(0.48)	1.23	(2.19)
- Diluted	2.53	(0.35)	(0.48)	1.23	(2.19)

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

Kamron Laboratories
MANAGING DIRECTOR

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



STATEMENT OF ASSETS AND LIABILITIES

(Rs. In lakh)

Sr. No.	Particulars	As at 31-03-2022	As at 31-03-2021
	ASSETS		
1	Non-Current Assets		
	Property, plant and equipment	-	-
	Capital work-in-progress	-	-
	Investment property	-	-
	Goodwill	-	-
	Other intangible Assets	443.26	364.13
	Intangible Assets under development	-	-
	Investments accounted for using equity method	-	-
	Biological Assets other than bearer plants	-	-
	Non-Current Financial Assets:		
	(i) Investments, Non-Current	-	-
	(ii) Trade receivables, Non-Current	-	-
	(iii) Loans, Non-Current	0.89	0.90
	Deferred tax Assets (net)	-	-
	Other Non-Current Assets	-	-
	Total Non-Current Assets	444.15	365.03
2	Current Assets		
	Inventories	25.90	39.22
	Current financial asset:		
	(i) Current investments	-	-
	(ii) Trade receivables, Current	7.13	158.28
	(iii) Cash and cash equivalents	4.39	(15.71)
	(iv) Bank balance other than above	0.30	-
	(v) Loans, Current	4.93	6.12
	(vi) Other Current financial Assets	0.39	-
	Current tax Assets (net)	-	-
	Other Current Assets	-	10.43
	Total Current Assets	43.04	198.34
	TOTAL ASSETS	487.19	563.37

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

Kamrun Khan
MANAGING DIRECTOR

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Sr. No.	Particulars	As at 31-03-2022	As at 31-03-2021
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	585	585
	Other Equity	(320.16)	(391.94)
	Total Equity	264.84	193.06
2	Liabilities		
	Non-Current Liabilities		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current		-
	(ii) Trade payables, Non-Current		-
	(a) total outstanding dues of micro enterprises and small enterprises		-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises		-
	(iii) Other Non-Current financial Liabilities		-
	Provisions, Non-Current	30.01	35.84
	Deferred tax Liabilities (net)	0.00	4.58
	Deferred government grants, non current	-	-
	Other Non-Current Liabilities	-	-
	Total Non-Current Liabilities	30.01	40.42
	Current Liabilities		
	Current financial Liabilities:		
	(i) Borrowings, Current	131.68	250.15
	(ii) Trade payables, Current	-	-
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	44.70	23.62
	(iii) Other Current financial Liabilities	-	-
	Other Current Liabilities	1.33	31.12
	Provisions, Current	14.63	25.00
	Current tax Liabilities (Net)	-	-
	Deferred government grants, current	-	-
	Total Current Liabilities	192.34	329.89
	Total Liabilities	222.35	370.31
	TOTAL EQUITY AND LIABILITIES	487.19	563.37

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

Kamrun K. Lankar
MANAGING DIRECTOR

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2022

(Amount in Rs.)

	Year ended 31 st March,2022	Year ended 31 st March,2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit(Loss) after tax	71,78,556	(128,33,580)
Adjustments for,		
Depreciation/ amortization	35,01,210	102,34,308
Depreciation Written back	(114,13,510)	-
Profit on W/o deferred tax Liabilities	(4,58,774)	-
Profit on Sale/Write off of fixed assets(net)	-	(6,307)
Interest expense	73,681	3,27,101
Interest income	(2)	(15)
Operating profit before working capital changes	(11,18,839)	(22,78,493)
Sub Total A		
(Increase)/ decrease in trade receivables	151,14,888	(15,20,865)
(Increase)/ decrease in inventories	13,31,566	69,95,754
(Increase)/ decrease in loans and advances	11,24,419	5,38,739
Increase/ (decrease)in trade and other payables	(143,37,844)	(66,76,822)
Sub Total B	32,33,029	(6,63,194)
Cash generated from operations	21,14,190	(29,41,687)
Direct taxes and fringe benefit tax paid	(465)	-
Net cash generated from operating activities-I (A+B)	21,13,725	(29,41,687)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	-	(1,15,098)
Sale proceeds from assets	-	12,89,997
□ Profit on Sales of assets	-	-
Interest income	2	15
Net cash (used in) investing activities -II Sub Total C	2	11,74,914
CASH FLOW FROM OPERATING AND INVESTING ACTIVITIES-III (I+II) (A+B=C)	21,13,727	(17,66,773)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayments of other borrowings	-	-
Proceeds/(repayments) of other borrowings (net)	-	-
Interest expense	(73,681)	(3,27,101)
Net cash (used in)/ from financing activities Sub Total D	(73,681)	(3,27,101)
Net increase/(decrease)in cash and cash equivalents (III+D)	20,40,046	(20,93,874)
Cash and cash equivalents at the beginning of the year	(15,71,233)	5,22,641
Cash and cash equivalents at the end of the year	4,68,813	(15,71,233)



ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Notes:

1	The figures for quarter ended on 31 st March, 2022 and 31 st March, 2021 are the balancing figures between the audited figures in respect of the full financial year ended on 31 st March, 2022 and 31 st March, 2021 and the year to date figures upto the third quarter of the financial year.
2	The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.
3	The Company does not have any subsidiary / associate.
4	Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 27 th May, 2022.
6	The Statutory Auditors have carried out an audit of the above results for the financial year ended 31 st March, 2022 and have issued an unmodified opinion on the same.
7	The name of the Company has been changed to 'Adline Chem Lab Limited' from 'Kamron Laboratories Limited' w.e.f. 13 th October, 2021.

**For ADLINE CHEM LAB LIMITED
(Formerly known as Kamron Laboratories Limited)**

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

Kamlesh J. Laskari
MANAGING DIRECTOR

**KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN: 00461198)**

Date : 27th May, 2022.
Place : Ahmedabad

INDEPENDENT AUDITOR'S REPORT**TO THE BOARD OF DIRECTORS OF ADLINE CHEM LAB LIMITED****Report on the audit of the Standalone Annual Financial Results****Opinion**

We have audited the accompanying standalone annual financial results of ADLINE CHEM LAB LIMITED (formerly known as Kamron Laboratories Limited) for the year ended 31st March, 2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). -

In our opinion and to the best of our information and according to the explanations given to us these standalone annual financial results:


- i. Are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. Give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit/ loss and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2022.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended March 31, 2022 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and



design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matter

The standalone annual financial results include the results for the quarter ended 31st March, 2022 and the corresponding quarter ended in the previous year being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year which were subject to limited review by us.



For RANGWALA & CO
Chartered Accountants
Firm's Registration No.115833W


ALIAKBAR TIMBAWALA
Partner
Membership Number 180746
UDIN: 22180746AJSRNS1973
Place : AHMEDABAD
Date:27-05-2022

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



27th May, 2022

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001

Company Code No. 524604

Dear Sir,

Sub: Declaration regarding Audit report with unmodified opinion with respect to Annual Audited Financial Results for the Financial Year ended 31st March, 2022

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and SEBI Circular No.CIR/CFD/CMD/56/2016 dated 27th May, 2016, it is hereby declared and confirmed that Auditors' Report obtained from M/s. Rangwala & Co., Chartered Accountants on Annual Audited Financial Results of the Company for the financial year ended 31st March, 2022 has an unmodified opinion.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For ADLINE CHEM LAB LIMITED

(Formerly known as Kamron Laboratories Limited)

KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN: 00461198)

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

Kamlesh J. Laskari
MANAGING DIRECTOR